1. Harrison TR, Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, et al. In: Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J, editors., et al., Harrison’s principles of internal medicine. 19th ed. New York: McGraw Hill Education; 2015.
2. Katzung BG. Basic & clinical pharmacology. In: Katzung BG (eds) MD, PhD, Professor Emeritus, Department of Cellular & Molecular Pharmacology, University of California, San Francisco. Fourteenth Edition. ed. New York: McGraw-Hill; 2018.
3. Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316–26.
4. Tsai TF, Wang TS, Hung ST, Tsai PI, Schenkel B, Zhang M, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci. 2011;63(1):40–6.
5. Wilton KM, Matteson EL. Malignancy incidence, management, and prevention in patients with rheumatoid arthritis. Rheumatol Ther. 2017;4(2):333–47.